Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in Advanced Solitary Fibrous Tumor (Italian Sarcoma Group Phase II)
2018-004571-12Phase 2Active
- Sponsor
- Italian Sarcoma Group
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin in hemangiopericytoma (HPC) and soft tissue sarcoma (STS), sponsored by Italian Sarcoma Group. Primary endpoint: Overall tumor response rate (RECIST v1.1). Started Jun 2021; status: active.
02
Drugs
eribulin
03
Conditions
hemangiopericytoma (HPC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2018-004571-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004571-12.